Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Cell and Gene Therapy CDMO Market Size Growth Rate by Type, 2018 VS 2022 VS 2033
1.2.2 Clinical Trial Material CDMOs
1.2.3 Development and Manufacturing CDMOs
1.2.4 Other
1.3 Market by Application
1.3.1 Global Cell and Gene Therapy CDMO Market Size Growth Rate by Application, 2018 VS 2022 VS 2033
1.3.2 Pharmaceutical Company
1.3.3 Biotechnology Company
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Cell and Gene Therapy CDMO Market Perspective (2018-2033)
2.2 Global Cell and Gene Therapy CDMO Growth Trends by Region
2.2.1 Cell and Gene Therapy CDMO Market Size by Region: 2018 VS 2022 VS 2033
2.2.2 Cell and Gene Therapy CDMO Historic Market Size by Region (2018-2023)
2.2.3 Cell and Gene Therapy CDMO Forecasted Market Size by Region (2024-2033)
2.3 Cell and Gene Therapy CDMO Market Dynamics
2.3.1 Cell and Gene Therapy CDMO Industry Trends
2.3.2 Cell and Gene Therapy CDMO Market Drivers
2.3.3 Cell and Gene Therapy CDMO Market Challenges
2.3.4 Cell and Gene Therapy CDMO Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Cell and Gene Therapy CDMO by Players
3.1.1 Global Cell and Gene Therapy CDMO Revenue by Players (2018-2023)
3.1.2 Global Cell and Gene Therapy CDMO Revenue Market Share by Players (2018-2023)
3.2 Global Cell and Gene Therapy CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Cell and Gene Therapy CDMO, Ranking by Revenue, 2021 VS 2022 VS 2023
3.4 Global Cell and Gene Therapy CDMO Market Concentration Ratio
3.4.1 Global Cell and Gene Therapy CDMO Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Cell and Gene Therapy CDMO Revenue in 2022
3.5 Global Key Players of Cell and Gene Therapy CDMO Head office and Area Served
3.6 Global Key Players of Cell and Gene Therapy CDMO, Product and Application
3.7 Global Key Players of Cell and Gene Therapy CDMO, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Cell and Gene Therapy CDMO Breakdown Data by Type
4.1 Global Cell and Gene Therapy CDMO Historic Market Size by Type (2018-2023)
4.2 Global Cell and Gene Therapy CDMO Forecasted Market Size by Type (2024-2033)
5 Cell and Gene Therapy CDMO Breakdown Data by Application
5.1 Global Cell and Gene Therapy CDMO Historic Market Size by Application (2018-2023)
5.2 Global Cell and Gene Therapy CDMO Forecasted Market Size by Application (2024-2033)
6 North America
6.1 North America Cell and Gene Therapy CDMO Market Size (2018-2033)
6.2 North America Cell and Gene Therapy CDMO Market Size by Type
6.2.1 North America Cell and Gene Therapy CDMO Market Size by Type (2018-2023)
6.2.2 North America Cell and Gene Therapy CDMO Market Size by Type (2024-2033)
6.2.3 North America Cell and Gene Therapy CDMO Market Share by Type (2018-2033)
6.3 North America Cell and Gene Therapy CDMO Market Size by Application
6.3.1 North America Cell and Gene Therapy CDMO Market Size by Application (2018-2023)
6.3.2 North America Cell and Gene Therapy CDMO Market Size by Application (2024-2033)
6.3.3 North America Cell and Gene Therapy CDMO Market Share by Application (2018-2033)
6.4 North America Cell and Gene Therapy CDMO Market Size by Country
6.4.1 North America Cell and Gene Therapy CDMO Market Size by Country: 2018 VS 2022 VS 2033
6.4.2 North America Cell and Gene Therapy CDMO Market Size by Country (2018-2023)
6.4.3 North America Cell and Gene Therapy CDMO Market Size by Country (2024-2033)
6.4.4 United States
6.4.5 Canada
7 Europe
7.1 Europe Cell and Gene Therapy CDMO Market Size (2018-2033)
7.2 Europe Cell and Gene Therapy CDMO Market Size by Type
7.2.1 Europe Cell and Gene Therapy CDMO Market Size by Type (2018-2023)
7.2.2 Europe Cell and Gene Therapy CDMO Market Size by Type (2024-2033)
7.2.3 Europe Cell and Gene Therapy CDMO Market Share by Type (2018-2033)
7.3 Europe Cell and Gene Therapy CDMO Market Size by Application
7.3.1 Europe Cell and Gene Therapy CDMO Market Size by Application (2018-2023)
7.3.2 Europe Cell and Gene Therapy CDMO Market Size by Application (2024-2033)
7.3.3 Europe Cell and Gene Therapy CDMO Market Share by Application (2018-2033)
7.4 Europe Cell and Gene Therapy CDMO Market Size by Country
7.4.1 Europe Cell and Gene Therapy CDMO Market Size by Country: 2018 VS 2022 VS 2033
7.4.2 Europe Cell and Gene Therapy CDMO Market Size by Country (2018-2023)
7.4.3 Europe Cell and Gene Therapy CDMO Market Size by Country (2024-2033)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Cell and Gene Therapy CDMO Market Size (2018-2033)
8.2 China Cell and Gene Therapy CDMO Market Size by Type
8.2.1 China Cell and Gene Therapy CDMO Market Size by Type (2018-2023)
8.2.2 China Cell and Gene Therapy CDMO Market Size by Type (2024-2033)
8.2.3 China Cell and Gene Therapy CDMO Market Share by Type (2018-2033)
8.3 China Cell and Gene Therapy CDMO Market Size by Application
8.3.1 China Cell and Gene Therapy CDMO Market Size by Application (2018-2023)
8.3.2 China Cell and Gene Therapy CDMO Market Size by Application (2024-2033)
8.3.3 China Cell and Gene Therapy CDMO Market Share by Application (2018-2033)
9 Asia (excluding China)
9.1 Asia Cell and Gene Therapy CDMO Market Size (2018-2033)
9.2 Asia Cell and Gene Therapy CDMO Market Size by Type
9.2.1 Asia Cell and Gene Therapy CDMO Market Size by Type (2018-2023)
9.2.2 Asia Cell and Gene Therapy CDMO Market Size by Type (2024-2033)
9.2.3 Asia Cell and Gene Therapy CDMO Market Share by Type (2018-2033)
9.3 Asia Cell and Gene Therapy CDMO Market Size by Application
9.3.1 Asia Cell and Gene Therapy CDMO Market Size by Application (2018-2023)
9.3.2 Asia Cell and Gene Therapy CDMO Market Size by Application (2024-2033)
9.3.3 Asia Cell and Gene Therapy CDMO Market Share by Application (2018-2033)
9.4 Asia Cell and Gene Therapy CDMO Market Size by Region
9.4.1 Asia Cell and Gene Therapy CDMO Market Size by Region: 2018 VS 2022 VS 2033
9.4.2 Asia Cell and Gene Therapy CDMO Market Size by Region (2018-2023)
9.4.3 Asia Cell and Gene Therapy CDMO Market Size by Region (2024-2033)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Cell and Gene Therapy CDMO Market Size (2018-2033)
10.2 Middle East, Africa, and Latin America Cell and Gene Therapy CDMO Market Size by Type
10.2.1 Middle East, Africa, and Latin America Cell and Gene Therapy CDMO Market Size by Type (2018-2023)
10.2.2 Middle East, Africa, and Latin America Cell and Gene Therapy CDMO Market Size by Type (2024-2033)
10.2.3 Middle East, Africa, and Latin America Cell and Gene Therapy CDMO Market Share by Type (2018-2033)
10.3 Middle East, Africa, and Latin America Cell and Gene Therapy CDMO Market Size by Application
10.3.1 Middle East, Africa, and Latin America Cell and Gene Therapy CDMO Market Size by Application (2018-2023)
10.3.2 Middle East, Africa, and Latin America Cell and Gene Therapy CDMO Market Size by Application (2024-2033)
10.3.3 Middle East, Africa, and Latin America Cell and Gene Therapy CDMO Market Share by Application (2018-2033)
10.4 Middle East, Africa, and Latin America Cell and Gene Therapy CDMO Market Size by Country
10.4.1 Middle East, Africa, and Latin America Cell and Gene Therapy CDMO Market Size by Country: 2018 VS 2022 VS 2033
10.4.2 Middle East, Africa, and Latin America Cell and Gene Therapy CDMO Market Size by Country (2018-2023)
10.4.3 Middle East, Africa, and Latin America Cell and Gene Therapy CDMO Market Size by Country (2024-2033)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Lonza
11.1.1 Lonza Company Details
11.1.2 Lonza Business Overview
11.1.3 Lonza Cell and Gene Therapy CDMO Introduction
11.1.4 Lonza Revenue in Cell and Gene Therapy CDMO Business (2018-2023)
11.1.5 Lonza Recent Developments
11.2 Charles River Laboratories
11.2.1 Charles River Laboratories Company Details
11.2.2 Charles River Laboratories Business Overview
11.2.3 Charles River Laboratories Cell and Gene Therapy CDMO Introduction
11.2.4 Charles River Laboratories Revenue in Cell and Gene Therapy CDMO Business (2018-2023)
11.2.5 Charles River Laboratories Recent Developments
11.3 Cytiva
11.3.1 Cytiva Company Details
11.3.2 Cytiva Business Overview
11.3.3 Cytiva Cell and Gene Therapy CDMO Introduction
11.3.4 Cytiva Revenue in Cell and Gene Therapy CDMO Business (2018-2023)
11.3.5 Cytiva Recent Developments
11.4 Catalent Biologics
11.4.1 Catalent Biologics Company Details
11.4.2 Catalent Biologics Business Overview
11.4.3 Catalent Biologics Cell and Gene Therapy CDMO Introduction
11.4.4 Catalent Biologics Revenue in Cell and Gene Therapy CDMO Business (2018-2023)
11.4.5 Catalent Biologics Recent Developments
11.5 FUJIFILM Diosynth Biotechnologies
11.5.1 FUJIFILM Diosynth Biotechnologies Company Details
11.5.2 FUJIFILM Diosynth Biotechnologies Business Overview
11.5.3 FUJIFILM Diosynth Biotechnologies Cell and Gene Therapy CDMO Introduction
11.5.4 FUJIFILM Diosynth Biotechnologies Revenue in Cell and Gene Therapy CDMO Business (2018-2023)
11.5.5 FUJIFILM Diosynth Biotechnologies Recent Developments
11.6 BioCentriq
11.6.1 BioCentriq Company Details
11.6.2 BioCentriq Business Overview
11.6.3 BioCentriq Cell and Gene Therapy CDMO Introduction
11.6.4 BioCentriq Revenue in Cell and Gene Therapy CDMO Business (2018-2023)
11.6.5 BioCentriq Recent Developments
11.7 RoslinCT
11.7.1 RoslinCT Company Details
11.7.2 RoslinCT Business Overview
11.7.3 RoslinCT Cell and Gene Therapy CDMO Introduction
11.7.4 RoslinCT Revenue in Cell and Gene Therapy CDMO Business (2018-2023)
11.7.5 RoslinCT Recent Developments
11.8 Thermo Scientific
11.8.1 Thermo Scientific Company Details
11.8.2 Thermo Scientific Business Overview
11.8.3 Thermo Scientific Cell and Gene Therapy CDMO Introduction
11.8.4 Thermo Scientific Revenue in Cell and Gene Therapy CDMO Business (2018-2023)
11.8.5 Thermo Scientific Recent Developments
11.9 Mesoblast
11.9.1 Mesoblast Company Details
11.9.2 Mesoblast Business Overview
11.9.3 Mesoblast Cell and Gene Therapy CDMO Introduction
11.9.4 Mesoblast Revenue in Cell and Gene Therapy CDMO Business (2018-2023)
11.9.5 Mesoblast Recent Developments
11.10 Cellularity
11.10.1 Cellularity Company Details
11.10.2 Cellularity Business Overview
11.10.3 Cellularity Cell and Gene Therapy CDMO Introduction
11.10.4 Cellularity Revenue in Cell and Gene Therapy CDMO Business (2018-2023)
11.10.5 Cellularity Recent Developments
11.11 Bluebird Bio
11.11.1 Bluebird Bio Company Details
11.11.2 Bluebird Bio Business Overview
11.11.3 Bluebird Bio Cell and Gene Therapy CDMO Introduction
11.11.4 Bluebird Bio Revenue in Cell and Gene Therapy CDMO Business (2018-2023)
11.11.5 Bluebird Bio Recent Developments
11.12 Editas Medicine
11.12.1 Editas Medicine Company Details
11.12.2 Editas Medicine Business Overview
11.12.3 Editas Medicine Cell and Gene Therapy CDMO Introduction
11.12.4 Editas Medicine Revenue in Cell and Gene Therapy CDMO Business (2018-2023)
11.12.5 Editas Medicine Recent Developments
11.13 Andelyn Biosciences
11.13.1 Andelyn Biosciences Company Details
11.13.2 Andelyn Biosciences Business Overview
11.13.3 Andelyn Biosciences Cell and Gene Therapy CDMO Introduction
11.13.4 Andelyn Biosciences Revenue in Cell and Gene Therapy CDMO Business (2018-2023)
11.13.5 Andelyn Biosciences Recent Developments
11.14 Wuxi Advanced Therapies
11.14.1 Wuxi Advanced Therapies Company Details
11.14.2 Wuxi Advanced Therapies Business Overview
11.14.3 Wuxi Advanced Therapies Cell and Gene Therapy CDMO Introduction
11.14.4 Wuxi Advanced Therapies Revenue in Cell and Gene Therapy CDMO Business (2018-2023)
11.14.5 Wuxi Advanced Therapies Recent Developments
11.15 AGC Biologics
11.15.1 AGC Biologics Company Details
11.15.2 AGC Biologics Business Overview
11.15.3 AGC Biologics Cell and Gene Therapy CDMO Introduction
11.15.4 AGC Biologics Revenue in Cell and Gene Therapy CDMO Business (2018-2023)
11.15.5 AGC Biologics Recent Developments
11.16 Pfizer CentreOne
11.16.1 Pfizer CentreOne Company Details
11.16.2 Pfizer CentreOne Business Overview
11.16.3 Pfizer CentreOne Cell and Gene Therapy CDMO Introduction
11.16.4 Pfizer CentreOne Revenue in Cell and Gene Therapy CDMO Business (2018-2023)
11.16.5 Pfizer CentreOne Recent Developments
11.17 Almac Group
11.17.1 Almac Group Company Details
11.17.2 Almac Group Business Overview
11.17.3 Almac Group Cell and Gene Therapy CDMO Introduction
11.17.4 Almac Group Revenue in Cell and Gene Therapy CDMO Business (2018-2023)
11.17.5 Almac Group Recent Developments
11.18 PCI Pharma Services
11.18.1 PCI Pharma Services Company Details
11.18.2 PCI Pharma Services Business Overview
11.18.3 PCI Pharma Services Cell and Gene Therapy CDMO Introduction
11.18.4 PCI Pharma Services Revenue in Cell and Gene Therapy CDMO Business (2018-2023)
11.18.5 PCI Pharma Services Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Cell and Gene Therapy CDMO Market Size Growth Rate by Type (US$ Million), 2018 VS 2022 VS 2033
Table 2. Key Players of Clinical Trial Material CDMOs
Table 3. Key Players of Development and Manufacturing CDMOs
Table 4. Key Players of Other
Table 5. Global Cell and Gene Therapy CDMO Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2033
Table 6. Global Cell and Gene Therapy CDMO Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2033
Table 7. Global Cell and Gene Therapy CDMO Market Size by Region (2018-2023) & (US$ Million)
Table 8. Global Cell and Gene Therapy CDMO Market Share by Region (2018-2023)
Table 9. Global Cell and Gene Therapy CDMO Forecasted Market Size by Region (2024-2033) & (US$ Million)
Table 10. Global Cell and Gene Therapy CDMO Market Share by Region (2024-2033)
Table 11. Cell and Gene Therapy CDMO Market Trends
Table 12. Cell and Gene Therapy CDMO Market Drivers
Table 13. Cell and Gene Therapy CDMO Market Challenges
Table 14. Cell and Gene Therapy CDMO Market Restraints
Table 15. Global Cell and Gene Therapy CDMO Revenue by Players (2018-2023) & (US$ Million)
Table 16. Global Cell and Gene Therapy CDMO Revenue Share by Players (2018-2023)
Table 17. Global Top Cell and Gene Therapy CDMO by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cell and Gene Therapy CDMO as of 2022)
Table 18. Global Cell and Gene Therapy CDMO Industry Ranking 2021 VS 2022 VS 2023
Table 19. Global 5 Largest Players Market Share by Cell and Gene Therapy CDMO Revenue (CR5 and HHI) & (2018-2023)
Table 20. Global Key Players of Cell and Gene Therapy CDMO, Headquarters and Area Served
Table 21. Global Key Players of Cell and Gene Therapy CDMO, Product and Application
Table 22. Global Key Players of Cell and Gene Therapy CDMO, Product and Application
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Cell and Gene Therapy CDMO Market Size by Type (2018-2023) & (US$ Million)
Table 25. Global Cell and Gene Therapy CDMO Revenue Market Share by Type (2018-2023)
Table 26. Global Cell and Gene Therapy CDMO Forecasted Market Size by Type (2024-2033) & (US$ Million)
Table 27. Global Cell and Gene Therapy CDMO Revenue Market Share by Type (2024-2033)
Table 28. Global Cell and Gene Therapy CDMO Market Size by Application (2018-2023) & (US$ Million)
Table 29. Global Cell and Gene Therapy CDMO Revenue Share by Application (2018-2023)
Table 30. Global Cell and Gene Therapy CDMO Forecasted Market Size by Application (2024-2033) & (US$ Million)
Table 31. Global Cell and Gene Therapy CDMO Revenue Share by Application (2024-2033)
Table 32. North America Cell and Gene Therapy CDMO Market Size by Type (2018-2023) & (US$ Million)
Table 33. North America Cell and Gene Therapy CDMO Market Size by Type (2024-2033) & (US$ Million)
Table 34. North America Cell and Gene Therapy CDMO Market Size by Application (2018-2023) & (US$ Million)
Table 35. North America Cell and Gene Therapy CDMO Market Size by Application (2024-2033) & (US$ Million)
Table 36. North America Cell and Gene Therapy CDMO Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2033
Table 37. North America Cell and Gene Therapy CDMO Market Size by Country (2018-2023) & (US$ Million)
Table 38. North America Cell and Gene Therapy CDMO Market Size by Country (2024-2033) & (US$ Million)
Table 39. Europe Cell and Gene Therapy CDMO Market Size by Type (2018-2023) & (US$ Million)
Table 40. Europe Cell and Gene Therapy CDMO Market Size by Type (2024-2033) & (US$ Million)
Table 41. Europe Cell and Gene Therapy CDMO Market Size by Application (2018-2023) & (US$ Million)
Table 42. Europe Cell and Gene Therapy CDMO Market Size by Application (2024-2033) & (US$ Million)
Table 43. Europe Cell and Gene Therapy CDMO Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2033
Table 44. Europe Cell and Gene Therapy CDMO Market Size by Country (2018-2023) & (US$ Million)
Table 45. Europe Cell and Gene Therapy CDMO Market Size by Country (2024-2033) & (US$ Million)
Table 46. China Cell and Gene Therapy CDMO Market Size by Type (2018-2023) & (US$ Million)
Table 47. China Cell and Gene Therapy CDMO Market Size by Type (2024-2033) & (US$ Million)
Table 48. China Cell and Gene Therapy CDMO Market Size by Application (2018-2023) & (US$ Million)
Table 49. China Cell and Gene Therapy CDMO Market Size by Application (2024-2033) & (US$ Million)
Table 50. Asia Cell and Gene Therapy CDMO Market Size by Type (2018-2023) & (US$ Million)
Table 51. Asia Cell and Gene Therapy CDMO Market Size by Type (2024-2033) & (US$ Million)
Table 52. Asia Cell and Gene Therapy CDMO Market Size by Application (2018-2023) & (US$ Million)
Table 53. Asia Cell and Gene Therapy CDMO Market Size by Application (2024-2033) & (US$ Million)
Table 54. Asia Cell and Gene Therapy CDMO Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2033
Table 55. Asia Cell and Gene Therapy CDMO Market Size by Region (2018-2023) & (US$ Million)
Table 56. Asia Cell and Gene Therapy CDMO Market Size by Region (2024-2033) & (US$ Million)
Table 57. Middle East, Africa, and Latin America Cell and Gene Therapy CDMO Market Size by Type (2018-2023) & (US$ Million)
Table 58. Middle East, Africa, and Latin America Cell and Gene Therapy CDMO Market Size by Type (2024-2033) & (US$ Million)
Table 59. Middle East, Africa, and Latin America Cell and Gene Therapy CDMO Market Size by Application (2018-2023) & (US$ Million)
Table 60. Middle East, Africa, and Latin America Cell and Gene Therapy CDMO Market Size by Application (2024-2033) & (US$ Million)
Table 61. Middle East, Africa, and Latin America Cell and Gene Therapy CDMO Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2033
Table 62. Middle East, Africa, and Latin America Cell and Gene Therapy CDMO Market Size by Country (2018-2023) & (US$ Million)
Table 63. Middle East, Africa, and Latin America Cell and Gene Therapy CDMO Market Size by Country (2024-2033) & (US$ Million)
Table 64. Lonza Company Details
Table 65. Lonza Business Overview
Table 66. Lonza Cell and Gene Therapy CDMO Product
Table 67. Lonza Revenue in Cell and Gene Therapy CDMO Business (2018-2023) & (US$ Million)
Table 68. Lonza Recent Developments
Table 69. Charles River Laboratories Company Details
Table 70. Charles River Laboratories Business Overview
Table 71. Charles River Laboratories Cell and Gene Therapy CDMO Product
Table 72. Charles River Laboratories Revenue in Cell and Gene Therapy CDMO Business (2018-2023) & (US$ Million)
Table 73. Charles River Laboratories Recent Developments
Table 74. Cytiva Company Details
Table 75. Cytiva Business Overview
Table 76. Cytiva Cell and Gene Therapy CDMO Product
Table 77. Cytiva Revenue in Cell and Gene Therapy CDMO Business (2018-2023) & (US$ Million)
Table 78. Cytiva Recent Developments
Table 79. Catalent Biologics Company Details
Table 80. Catalent Biologics Business Overview
Table 81. Catalent Biologics Cell and Gene Therapy CDMO Product
Table 82. Catalent Biologics Revenue in Cell and Gene Therapy CDMO Business (2018-2023) & (US$ Million)
Table 83. Catalent Biologics Recent Developments
Table 84. FUJIFILM Diosynth Biotechnologies Company Details
Table 85. FUJIFILM Diosynth Biotechnologies Business Overview
Table 86. FUJIFILM Diosynth Biotechnologies Cell and Gene Therapy CDMO Product
Table 87. FUJIFILM Diosynth Biotechnologies Revenue in Cell and Gene Therapy CDMO Business (2018-2023) & (US$ Million)
Table 88. FUJIFILM Diosynth Biotechnologies Recent Developments
Table 89. BioCentriq Company Details
Table 90. BioCentriq Business Overview
Table 91. BioCentriq Cell and Gene Therapy CDMO Product
Table 92. BioCentriq Revenue in Cell and Gene Therapy CDMO Business (2018-2023) & (US$ Million)
Table 93. BioCentriq Recent Developments
Table 94. RoslinCT Company Details
Table 95. RoslinCT Business Overview
Table 96. RoslinCT Cell and Gene Therapy CDMO Product
Table 97. RoslinCT Revenue in Cell and Gene Therapy CDMO Business (2018-2023) & (US$ Million)
Table 98. RoslinCT Recent Developments
Table 99. Thermo Scientific Company Details
Table 100. Thermo Scientific Business Overview
Table 101. Thermo Scientific Cell and Gene Therapy CDMO Product
Table 102. Thermo Scientific Revenue in Cell and Gene Therapy CDMO Business (2018-2023) & (US$ Million)
Table 103. Thermo Scientific Recent Developments
Table 104. Mesoblast Company Details
Table 105. Mesoblast Business Overview
Table 106. Mesoblast Cell and Gene Therapy CDMO Product
Table 107. Mesoblast Revenue in Cell and Gene Therapy CDMO Business (2018-2023) & (US$ Million)
Table 108. Mesoblast Recent Developments
Table 109. Cellularity Company Details
Table 110. Cellularity Business Overview
Table 111. Cellularity Cell and Gene Therapy CDMO Product
Table 112. Cellularity Revenue in Cell and Gene Therapy CDMO Business (2018-2023) & (US$ Million)
Table 113. Cellularity Recent Developments
Table 114. Bluebird Bio Company Details
Table 115. Bluebird Bio Business Overview
Table 116. Bluebird Bio Cell and Gene Therapy CDMO Product
Table 117. Bluebird Bio Revenue in Cell and Gene Therapy CDMO Business (2018-2023) & (US$ Million)
Table 118. Bluebird Bio Recent Developments
Table 119. Editas Medicine Company Details
Table 120. Editas Medicine Business Overview
Table 121. Editas Medicine Cell and Gene Therapy CDMO Product
Table 122. Editas Medicine Revenue in Cell and Gene Therapy CDMO Business (2018-2023) & (US$ Million)
Table 123. Editas Medicine Recent Developments
Table 124. Andelyn Biosciences Company Details
Table 125. Andelyn Biosciences Business Overview
Table 126. Andelyn Biosciences Cell and Gene Therapy CDMO Product
Table 127. Andelyn Biosciences Revenue in Cell and Gene Therapy CDMO Business (2018-2023) & (US$ Million)
Table 128. Andelyn Biosciences Recent Developments
Table 129. Wuxi Advanced Therapies Company Details
Table 130. Wuxi Advanced Therapies Business Overview
Table 131. Wuxi Advanced Therapies Cell and Gene Therapy CDMO Product
Table 132. Wuxi Advanced Therapies Revenue in Cell and Gene Therapy CDMO Business (2018-2023) & (US$ Million)
Table 133. Wuxi Advanced Therapies Recent Developments
Table 134. AGC Biologics Company Details
Table 135. AGC Biologics Business Overview
Table 136. AGC Biologics Cell and Gene Therapy CDMO Product
Table 137. AGC Biologics Revenue in Cell and Gene Therapy CDMO Business (2018-2023) & (US$ Million)
Table 138. AGC Biologics Recent Developments
Table 139. Pfizer CentreOne Company Details
Table 140. Pfizer CentreOne Business Overview
Table 141. Pfizer CentreOne Cell and Gene Therapy CDMO Product
Table 142. Pfizer CentreOne Revenue in Cell and Gene Therapy CDMO Business (2018-2023) & (US$ Million)
Table 143. Pfizer CentreOne Recent Developments
Table 144. Almac Group Company Details
Table 145. Almac Group Business Overview
Table 146. Almac Group Cell and Gene Therapy CDMO Product
Table 147. Almac Group Revenue in Cell and Gene Therapy CDMO Business (2018-2023) & (US$ Million)
Table 148. Almac Group Recent Developments
Table 149. PCI Pharma Services Company Details
Table 150. PCI Pharma Services Business Overview
Table 151. PCI Pharma Services Cell and Gene Therapy CDMO Product
Table 152. PCI Pharma Services Revenue in Cell and Gene Therapy CDMO Business (2018-2023) & (US$ Million)
Table 153. PCI Pharma Services Recent Developments
Table 154. Research Programs/Design for This Report
Table 155. Key Data Information from Secondary Sources
Table 156. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Cell and Gene Therapy CDMO Market Size Growth Rate by Type, 2018 VS 2022 VS 2033 (US$ Million)
Figure 2. Global Cell and Gene Therapy CDMO Market Share by Type: 2022 VS 2033
Figure 3. Clinical Trial Material CDMOs Features
Figure 4. Development and Manufacturing CDMOs Features
Figure 5. Other Features
Figure 6. Global Cell and Gene Therapy CDMO Market Size Growth Rate by Application, 2018 VS 2022 VS 2033 (US$ Million)
Figure 7. Global Cell and Gene Therapy CDMO Market Share by Application: 2022 VS 2033
Figure 8. Pharmaceutical Company Case Studies
Figure 9. Biotechnology Company Case Studies
Figure 10. Other Case Studies
Figure 11. Cell and Gene Therapy CDMO Report Years Considered
Figure 12. Global Cell and Gene Therapy CDMO Market Size (US$ Million), Year-over-Year: 2018-2033
Figure 13. Global Cell and Gene Therapy CDMO Market Size, (US$ Million), 2018 VS 2022 VS 2033
Figure 14. Global Cell and Gene Therapy CDMO Market Share by Region: 2022 VS 2033
Figure 15. Global Cell and Gene Therapy CDMO Market Share by Players in 2022
Figure 16. Global Top Cell and Gene Therapy CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cell and Gene Therapy CDMO as of 2022)
Figure 17. The Top 10 and 5 Players Market Share by Cell and Gene Therapy CDMO Revenue in 2022
Figure 18. North America Cell and Gene Therapy CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 19. North America Cell and Gene Therapy CDMO Market Share by Type (2018-2033)
Figure 20. North America Cell and Gene Therapy CDMO Market Share by Application (2018-2033)
Figure 21. North America Cell and Gene Therapy CDMO Market Share by Country (2018-2033)
Figure 22. United States Cell and Gene Therapy CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 23. Canada Cell and Gene Therapy CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 24. Europe Cell and Gene Therapy CDMO Market Size YoY (2018-2033) & (US$ Million)
Figure 25. Europe Cell and Gene Therapy CDMO Market Share by Type (2018-2033)
Figure 26. Europe Cell and Gene Therapy CDMO Market Share by Application (2018-2033)
Figure 27. Europe Cell and Gene Therapy CDMO Market Share by Country (2018-2033)
Figure 28. Germany Cell and Gene Therapy CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 29. France Cell and Gene Therapy CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 30. U.K. Cell and Gene Therapy CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 31. Italy Cell and Gene Therapy CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 32. Russia Cell and Gene Therapy CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 33. Nordic Countries Cell and Gene Therapy CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 34. China Cell and Gene Therapy CDMO Market Size YoY (2018-2033) & (US$ Million)
Figure 35. China Cell and Gene Therapy CDMO Market Share by Type (2018-2033)
Figure 36. China Cell and Gene Therapy CDMO Market Share by Application (2018-2033)
Figure 37. Asia Cell and Gene Therapy CDMO Market Size YoY (2018-2033) & (US$ Million)
Figure 38. Asia Cell and Gene Therapy CDMO Market Share by Type (2018-2033)
Figure 39. Asia Cell and Gene Therapy CDMO Market Share by Application (2018-2033)
Figure 40. Asia Cell and Gene Therapy CDMO Market Share by Region (2018-2033)
Figure 41. Japan Cell and Gene Therapy CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 42. South Korea Cell and Gene Therapy CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 43. China Taiwan Cell and Gene Therapy CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 44. Southeast Asia Cell and Gene Therapy CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 45. India Cell and Gene Therapy CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 46. Australia Cell and Gene Therapy CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 47. Middle East, Africa, and Latin America Cell and Gene Therapy CDMO Market Size YoY (2018-2033) & (US$ Million)
Figure 48. Middle East, Africa, and Latin America Cell and Gene Therapy CDMO Market Share by Type (2018-2033)
Figure 49. Middle East, Africa, and Latin America Cell and Gene Therapy CDMO Market Share by Application (2018-2033)
Figure 50. Middle East, Africa, and Latin America Cell and Gene Therapy CDMO Market Share by Country (2018-2033)
Figure 51. Brazil Cell and Gene Therapy CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 52. Mexico Cell and Gene Therapy CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 53. Turkey Cell and Gene Therapy CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 54. Saudi Arabia Cell and Gene Therapy CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 55. Israel Cell and Gene Therapy CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 56. GCC Countries Cell and Gene Therapy CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 57. Lonza Revenue Growth Rate in Cell and Gene Therapy CDMO Business (2018-2023)
Figure 58. Charles River Laboratories Revenue Growth Rate in Cell and Gene Therapy CDMO Business (2018-2023)
Figure 59. Cytiva Revenue Growth Rate in Cell and Gene Therapy CDMO Business (2018-2023)
Figure 60. Catalent Biologics Revenue Growth Rate in Cell and Gene Therapy CDMO Business (2018-2023)
Figure 61. FUJIFILM Diosynth Biotechnologies Revenue Growth Rate in Cell and Gene Therapy CDMO Business (2018-2023)
Figure 62. BioCentriq Revenue Growth Rate in Cell and Gene Therapy CDMO Business (2018-2023)
Figure 63. RoslinCT Revenue Growth Rate in Cell and Gene Therapy CDMO Business (2018-2023)
Figure 64. Thermo Scientific Revenue Growth Rate in Cell and Gene Therapy CDMO Business (2018-2023)
Figure 65. Mesoblast Revenue Growth Rate in Cell and Gene Therapy CDMO Business (2018-2023)
Figure 66. Cellularity Revenue Growth Rate in Cell and Gene Therapy CDMO Business (2018-2023)
Figure 67. Bluebird Bio Revenue Growth Rate in Cell and Gene Therapy CDMO Business (2018-2023)
Figure 68. Editas Medicine Revenue Growth Rate in Cell and Gene Therapy CDMO Business (2018-2023)
Figure 69. Andelyn Biosciences Revenue Growth Rate in Cell and Gene Therapy CDMO Business (2018-2023)
Figure 70. Wuxi Advanced Therapies Revenue Growth Rate in Cell and Gene Therapy CDMO Business (2018-2023)
Figure 71. AGC Biologics Revenue Growth Rate in Cell and Gene Therapy CDMO Business (2018-2023)
Figure 72. Pfizer CentreOne Revenue Growth Rate in Cell and Gene Therapy CDMO Business (2018-2023)
Figure 73. Almac Group Revenue Growth Rate in Cell and Gene Therapy CDMO Business (2018-2023)
Figure 74. PCI Pharma Services Revenue Growth Rate in Cell and Gene Therapy CDMO Business (2018-2023)
Figure 75. Bottom-up and Top-down Approaches for This Report
Figure 76. Data Triangulation
Figure 77. Key Executives Interviewed